" class="no-js "lang="en-US"> Robocath - Medtech Alert
Saturday, June 21, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Robocath | Pharmtech Focus

Robocath

About Robocath

Robocath

Robocath is a french medtech which designs, develops and commercializes robotic solutions to treat cardiovascular diseases.

R-One™ is the first european robotic-assisted solution for PCI. The company obtained the CE-mark for R-One™ in February 2019. It is designed to operate with precision and perform specific movements creating better interventional conditions (radioprotection). Thanks to its open architecture, R-One™ is compatible with market leading devices and cath labs.

Robocath aims to become the world leader in vascular robotics and develop the remote treatment of vascular emergencies, guaranteeing the best care pathway for all.

We are convinced that the future standard for minimally-invasive procedures is robot-based.

Related Story

Cardiovascular

 Robocath Achieves Positive Results in R-Evolution Multicenter European Clinical Study on Robotic Coronary Angioplasty | Pharmtech Focus

Robocath Achieves Positive Results in R-Evolution Multicenter European Clinical Study on Robotic Coronary Angioplasty

May 18 2022

Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of […]

Manufacturing

 Robocath Concludes First European Clinical Study to Demonstrate Safety and Efficacy of Robotic Coronary Angioplasty Performed with R-One | Pharmtech Focus

Robocath Concludes First European Clinical Study to Demonstrate Safety and Efficacy of Robotic Coronary Angioplasty Performed with R-One

January 12 2022

Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of […]

Equipment

 Robocath Successfully Performs First Carotid Stenting in France with R-One™ Robot at Rennes University Hospital | Pharmtech Focus

Robocath Successfully Performs First Carotid Stenting in France with R-One™ Robot at Rennes University Hospital

November 24 2021

Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of […]

Equipment

 Robocath and Rennes University Hospital Launch Co-development Research Program into Treatment of Strokes in Partnership with Philips France | Pharmtech Focus

Robocath and Rennes University Hospital Launch Co-development Research Program into Treatment of Strokes in Partnership with Philips France

July 7 2021

Robocath, a company that designs, develops and commercializes robotic solutions to treat cardiovascular diseases, and […]

News

 Robocath Successfully Completes First Robotic Coronary Angioplasties in Belgium | Pharmtech Focus

Robocath Completes First Robotic Angioplasties in Belgium

May 4 2021

Robocath, a company that designs, develops and commercializes cardiovascular robotic platforms for the treatment of […]